Softwr

Healthcare · head to head

Aidoc vs Paige

Aidoc logo

Aidoc

Healthcare

FDA cleared radiology AI for triage and notification of time critical findings

From
On request
Rated
-
Full reviewWebsite
Paige logo

Paige

Healthcare

Digital pathology AI holding the first FDA De Novo authorisation for a pathology algorithm, now part of Tempus

From
On request
Rated
-
Full reviewWebsite

The short version

  • Each has a real cost: Aidoc the clearances are for triage and notification in the CADt category, so the software may reorder a worklist but may not deliver a diagnosis or replace a read, and business cases built on reduced radiologist workload do not survive contact with the regulatory wording.; Paige the FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • They diverge on capability: Aidoc covers Triage and notification, Paige covers Paige Prostate Detect.
  • Prices and features above were last checked on 1 September 2026.

Where they differ

Only the attributes on which Aidoc and Paige actually diverge.

Attributes where Aidoc and Paige differ
AttributeAidocPaige
PlatformsWeb, iOS, AndroidWeb, Cloud, On-premise

Identical on both: starting price (On request), pricing model (quote), free tier (No), user rating (Not yet rated), category (Healthcare).

What each one covers

Drawn from each product's published feature list. An absence here means we hold no record of it - not that the product lacks it.

Only in Aidoc

  • Triage and notification
  • Intracranial haemorrhage
  • Pulmonary embolism
  • Large vessel occlusion
  • Pneumothorax on X-ray
  • aiOS platform
  • Clinical workflow notifications

Only in Paige

  • Paige Prostate Detect
  • Paige Prostate Grade and Quantify
  • Perineural invasion detection
  • Breast and lymph node applications
  • FullFocus viewer
  • Foundation models
  • OmniScreen
  • Paige Alba

What people use each for

The jobs each tool is most often brought in to do.

Aidoc

  • A regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictatesnot Paige
  • A trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologistnot Paige
  • An oncology imaging programme that wants incidental pulmonary embolism caught on staging CTs ordered for a different questionnot Paige
  • A health system that has bought AI from several vendors and wants one PACS integration through aiOS rather than one integration per algorithmnot Paige

Paige

  • A reference laboratory processing high volumes of prostate core needle biopsies where a second read on every case is not staffablenot Aidoc
  • A pathology department already digitised that wants a documented safety net against missed small foci of cancernot Aidoc
  • A hospital laboratory struggling to recruit uropathology subspecialists and needing consistency across generalist reportingnot Aidoc
  • A pharmaceutical company needing consistent biomarker scoring across trial sites rather than site-by-site pathologist variabilitynot Aidoc

Where each one falls short

Documented limitations, not opinions. Every one is a constraint you would hit in normal use.

Aidoc

  • The clearances are for triage and notification in the CADt category, so the software may reorder a worklist but may not deliver a diagnosis or replace a read, and business cases built on reduced radiologist workload do not survive contact with the regulatory wording.
  • Triage algorithms are tuned for sensitivity, so false positives are routine, and each one interrupts a radiologist. Sites that do not measure positive predictive value in their own case mix see clinician trust erode within months.
  • Pricing is per algorithm and per study volume with no published rate card, so the cost of a multi algorithm deployment escalates sharply and cannot be benchmarked before a sales conversation.
  • The clinical benefit accrues to stroke, trauma and cardiology service lines while the cost usually lands in the radiology or IT budget, which makes internal funding harder than the return on investment slides suggest.
  • Performance depends on scanner protocols and reconstruction settings, so results validated at one site do not transfer, and each deployment needs local validation work that is rarely budgeted for.

Paige

  • The FDA authorisation is confined to prostate core needle biopsies, on compatible scanners, viewed through FullFocus, as an adjunct only; every other tissue type and every grading claim is outside that authorisation in the United States.
  • The algorithm is worthless without a digital pathology programme already running, and slide scanning, storage and workflow typically cost far more than the software licence.
  • Tempus acquired Paige in 2025, so the roadmap now competes for attention inside a genomics-led business, and the pathology-only buyer is no longer the primary customer.
  • Scanner compatibility is a hard constraint rather than a preference, and a laboratory with an unsupported scanner fleet cannot use the authorised indication at all.
  • Pricing is per case or per slide and unpublished, so a laboratory cannot model cost per reported case without entering a sales process.

Pricing, plan by plan

Aidoc

On request
  • Aidoc$undefined/year
    • Annual subscription priced by algorithm and by study volume
    • aiOS platform integration licensed separately from individual algorithms
    • Multi algorithm bundles negotiated for enterprise deployments

Paige

On request
  • Paige clinical applications$undefined/year
    • Priced per case or per slide analysed under annual agreement
    • Prostate, breast and other applications licensed separately
    • Requires compatible whole slide scanner and the FullFocus viewer for the authorised indication

Which should you pick?

Choose Aidoc if

  • You need triage and notification.
  • You work on Web, iOS, Android.
  • You also want intracranial haemorrhage.
Aidoc review

Choose Paige if

  • You need paige prostate detect.
  • You work on Web, Cloud, On-premise.
  • You also want paige prostate grade and quantify.
Paige review

Questions people ask

Is Aidoc or Paige better?
Neither clearly leads. Aidoc starts at On request and Paige at On request, and user ratings are close enough to be indistinguishable. Choose on capability and platform support.
Which is cheaper, Aidoc or Paige?
Aidoc starts at On request and Paige at On request.
Does Aidoc or Paige run on more platforms?
Aidoc runs on Web, iOS, Android. Paige runs on Web, Cloud, On-premise.
What is Aidoc best used for?
Aidoc is most often used for a regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictates, a trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologist, an oncology imaging programme that wants incidental pulmonary embolism caught on staging cts ordered for a different question, a health system that has bought ai from several vendors and wants one pacs integration through aios rather than one integration per algorithm. Of those, a regional stroke centre that wants large vessel occlusion flagged and the neurointervention team notified before the radiologist dictates and a trauma centre wanting cervical spine fracture and intra abdominal free gas prioritised in an overnight queue read by one on call radiologist are not what Paige is typically brought in for.
What can Aidoc do that Paige cannot?
Aidoc covers Triage and notification, Intracranial haemorrhage, Pulmonary embolism, Large vessel occlusion. Paige covers Paige Prostate Detect, Paige Prostate Grade and Quantify, Perineural invasion detection, Breast and lymph node applications.

Answered from the vendors’ own pages

Aidoc: Is Aidoc FDA cleared?

Yes, it holds multiple 510(k) clearances, but they are for computer aided triage and notification. It may prioritise a worklist and notify a team. It may not provide a diagnostic interpretation or replace a radiologist read.

Paige: What exactly is FDA authorised?

Paige Prostate Detect, as an adjunct for identifying areas of interest on digitised prostate core needle biopsy slides, viewed through the Paige FullFocus viewer on a compatible scanner. Nothing else in the portfolio holds that authorisation in the United States.

Aidoc: Does it reduce radiologist workload?

No. Every study still needs a full read. The benefit is in the order studies are read and how quickly a receiving specialty is activated, not in reading fewer studies.

Paige: Is the European position broader?

Yes. The Paige Prostate suite including grading and quantification received IVDR certification in 2025, which covers more than the United States authorisation.

Aidoc: Can I run other vendors AI through it?

Yes, that is what the aiOS platform layer is for, and for health systems with several AI vendors it is often the main reason to buy Aidoc at all.

Paige: What did the pivotal study measure?

Pathologist cancer detection on individual slide images improved, with reported reductions in false negative and false positive readings. It measured pathologist performance with the tool, not standalone algorithm accuracy.

Aidoc: Is pricing published?

No. It is quoted per algorithm and by annual study volume, and enterprise bundles are negotiated case by case.

Paige: Who owns Paige now?

Tempus AI acquired Paige in 2025. Products remain branded Paige.

Share

Related pages

More on Aidoc

More on Paige

Keep looking

Other head to heads